FDA Warns Enessa For Claims Violations, Diminish-Rosacea Treatment
This article was originally published in The Rose Sheet
Executive Summary
Natural brand Enessa may have to discontinue or relabel its Diminish-Rosacea Treatment, as the name constitutes an unapproved drug claim, FDA suggests in a warning letter. Other claims cited by the agency pertain to cellular repair, collagen synthesis, anti-inflammatory benefits and improved micro-circulation.
You may also be interested in...
‘Ant-type Insects’ And Expired Ingredients: FDA Warns Bioque Following Inspection
Agency inspectors observed a range of insanitary conditions and practices at the Blacksburg, Virginia-based manufacturing site that turns out Bioque and Vouray skin-care products, causing the products to be adulterated, according to an FDA warning letter.
FDA’s July Warning Letters To Skin-Care Marketers Continue To Surface
Add Menscience Androceuticals, La Bella Figura and Healing Scents to the list of skin-care marketers hit with FDA warning letters in July. The agency’s policy is to wait for warning letter recipients to acknowledge receipt before posting the communications to its website.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.